论文部分内容阅读
近年来,分子生物学技术的飞速发展为微观分子水平上的基于靶点的药物研究奠定了基础。小分子药物通常是信号转导的调节剂,它能够特异性地调节信号传导通路,从而达到治疗疾病的目的。目前已经发现的药物靶点大约有500个[1],在此基础之上建立了大量的以药物作用靶点为研究对象的分子水平的筛选模型,根据小分子与靶点结合的特性,来判断化合物的生物活性,从而筛选出高选择性的分子靶向药物。这种基于靶点相互作用的筛选模型可以极大地提高新药的开发速度,并且对于阐明小分子与靶点的作用机制具有重要意义。
In recent years, the rapid development of molecular biology technology has laid the foundation for target-based drug research at the micro-molecular level. Small molecule drugs are usually signal transduction regulators, which can specifically regulate signaling pathways, so as to achieve the purpose of treating diseases. At present, about 500 drug targets have been found [1]. On the basis of this, a large number of molecular screening models have been established based on drug target targets. According to the combination of small molecules and targets, To determine the biological activity of compounds, thus screening highly selective molecular targeted drugs. This screening model based on target interactions can greatly speed up the development of new drugs and is of great significance to clarify the mechanism of action of small molecules and targets.